An artificial intelligence system was effective for real-time monitoring of endoscopic "blind spots" and improved detection of early gastric cancer during esophagogastroduodenoscopy.
Dr Daniel Catenacci, the lead investigator in a clinical trial for the drug bemarituzumab, has been charged with violating the antifraud provisions of the federal securities laws.
The addition of pembrolizumab (Keytruda) to trastuzumab (Herceptin) and platinum-based chemotherapy led to a significant improvement in overall response rate.